Endometriosis affects roughly one in ten reproductive-age women, yet diagnosis still averages seven to ten years from symptom onset — largely because definitive confirmation requires laparoscopic surgery. Any credible move toward a non-invasive diagnostic test would represent a meaningful clinical advance, making this pilot study worth careful attention.
In a case-control design enrolling 176 women with confirmed endometriosis and 124 controls — stratified into healthy individuals and those with benign gynecological conditions to reduce confounding — researchers used next-generation sequencing to profile microRNAs (miRNAs) in saliva. Ten miRNAs showed significant association with disease activity. Seven of these, including hsa-miR-130a-3p, hsa-miR-130b-3p, and members of the miR-200 family, had previously been linked to endometriosis in tissue or blood studies. Three additional miRNAs mapped to inflammatory and oncogenic pathways. Critically, expression levels formed a gradient across untreated, pharmacologically treated, and surgically treated subgroups, implying these markers reflect real-time disease modulation rather than static genetic background. Pathway analysis converged on PTEN as a central regulatory target, implicating the PI3K/AKT/mTOR signaling axis in lesion persistence.
The miR-200 family's involvement is biologically coherent: these miRNAs regulate epithelial-to-mesenchymal transition, a process increasingly implicated in endometriotic lesion implantation and invasiveness. The PTEN/PI3K/AKT connection similarly aligns with existing mechanistic literature on ectopic tissue survival and estrogen-driven proliferation. What distinguishes this study is the salivary matrix — accessible, non-invasive, and increasingly validated for systemic disease biomarkers — and the relatively robust sample size for a pilot. Limitations are substantial, however: this remains a single-center pilot without independent validation cohort, sequencing was performed on a heterogeneous treated population introducing therapy as a confounder, and salivary miRNA stability across collection protocols is not yet standardized. Whether these ten markers hold diagnostic sensitivity and specificity in a prospective clinical setting is unknown. Incremental but directionally important — particularly for accelerating the diagnostic timeline.